Independent healthcare communications specialist Fishawack has acquired US-based healthcare communications agency, 2e Creative, for an undisclosed sum.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh